Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Asset Writedowns and Impairment (2022 - 2025)

Historic Asset Writedowns and Impairment for BioNexus Gene Lab (BGLC) over the last 4 years, with Q3 2025 value amounting to $175818.0.

  • BioNexus Gene Lab's Asset Writedowns and Impairment rose 730598.15% to $175818.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $97541.0, marking a year-over-year increase of 102699.02%. This contributed to the annual value of $40173.0 for FY2024, which is 54857.93% up from last year.
  • BioNexus Gene Lab's Asset Writedowns and Impairment amounted to $175818.0 in Q3 2025, which was up 730598.15% from -$82670.0 recorded in Q4 2024.
  • Over the past 5 years, BioNexus Gene Lab's Asset Writedowns and Impairment peaked at $175818.0 during Q3 2025, and registered a low of -$82670.0 during Q4 2024.
  • In the last 4 years, BioNexus Gene Lab's Asset Writedowns and Impairment had a median value of $2196.5 in 2023 and averaged $16967.2.
  • In the last 5 years, BioNexus Gene Lab's Asset Writedowns and Impairment plummeted by 419460.13% in 2024 and then skyrocketed by 730598.15% in 2025.
  • Over the past 4 years, BioNexus Gene Lab's Asset Writedowns and Impairment (Quarter) stood at $4165.0 in 2022, then plummeted by 51.52% to $2019.0 in 2023, then tumbled by 4194.6% to -$82670.0 in 2024, then surged by 312.67% to $175818.0 in 2025.
  • Its Asset Writedowns and Impairment stands at $175818.0 for Q3 2025, versus -$82670.0 for Q4 2024 and $2374.0 for Q3 2024.